Novo Nordisk A/S
NOVO B.CO - OMX NORDIC EXCHANGE COPENHAGEN A/S
Industry: Pharmaceuticals
Market Cap: 1742.4 B
IPO Date: May 17, 1974
Country: DK
Currency: DKK
Shares Outstanding: 3.4 B
6 month performance
Recent News
Here Are 2 Defensive Positions That Are Worth A Look Now
9/21/2025
It is smart to start considering some more defensive value positions in the portfolio. Check out the insights on NVO and UPS stocks here.
Source: SeekingAlpha
Eli Lilly: Orforglipron Sets Path Of Continued Revenue Growth In T2D And Obesity
9/21/2025
Discover why LLY stock is rated Buy as sales surge in diabetes & obesity drugs and new treatments drive future growth.
Source: SeekingAlpha
Novo Nordisk: Don't Be Deterred By Outlook Downgrades
9/19/2025
Novo Nordisk A/S's outlook downgrades are concerning, but strong growth potential and positive study results make NVO stock worth considering. Learn more about NVO stock here.
Source: SeekingAlpha
Wall Street Breakfast Podcast: FedEx Delivers Earnings Surprise
9/19/2025
FedEx rallies after topping profit expectations, updating on business. Activist investor Biglari targets Cracker Barrel CEO. Novo Nordisk reduces team for obesity and diabetes education.
Source: SeekingAlpha
Novo Nordisk: Attractive Buying Opportunity In A Distracted Market
9/18/2025
Novo Nordisk has a strong financial position and portfolio of weight-loss and diabetes treatments. See why NVOâs stock dip may be a buying opportunity.
Source: SeekingAlpha
It Is Time To Buy Novo Nordisk Hand Over Fist
9/18/2025
Novo Nordisk A/S is a strong buy for 2024, with cutting-edge drug approvals, cost savings, and robust long-term growth potential. Click for my NVO stock update.
Source: SeekingAlpha
Novo Nordisk A/S (NVO) R&D Investor Event Call (Transcript)
9/18/2025
Get the latest on Novo Nordisk's R&D, obesity, and diabetes pipeline, including updates on
Source: SeekingAlpha
Novo Nordisk A/S - Special Call
9/17/2025
Novo Nordisk A/S - Special CallCompany ParticipantsMartin Lange - EVP of R&D, CSO and Member of the Management BoardConference Call ParticipantsMartin...
Source: SeekingAlpha
Eli Lilly: New Orforglipron Data In Focus As Commercial Business Outperforms
9/17/2025
Eli Lilly's strong Q2 results, raised guidance, and robust demand for tirzepatide reinforce confidence in its commercial momentum and market leadership. Learn more about LLY stock here.
Source: SeekingAlpha
Wall Street Lunch: Cup Of Coffee To Get Costlier
9/16/2025
Coffee futures prices continue to surge in 2025, with both arabica and robusta reaching multi-year highs. The impact is being felt in the U.S. as retail coffee prices have also spiked.
Source: SeekingAlpha
The Secret Blue-Chip Rally No One Knows About: 4 Amazing Ideas To Consider
9/15/2025
Is Wall Street in a bubble? Read about four stocks that could help investors looking at more market upside.
Source: SeekingAlpha
How Trump's Drug Pricing Policies Could Trigger An Epic Pharma Collapse
9/15/2025
Explore how President Trump's drug pricing policy impacts pharma stocks like PFE & LLY. Learn investment strategies as regulatory risks rise. Click for more.
Source: SeekingAlpha
Novo Nordisk: The Market Is Giving Us A Free Lunch
9/15/2025
Novo Nordisk's stock is severely oversold as the market overreacts to short-term news, which has created a rare buying opportunity. Learn more about NVO stock here.
Source: SeekingAlpha
How I Would Invest $100,000 In Today's Overpriced Market
9/14/2025
US stocks face high valuations and stagflation risks. Check out the strategies for investing, stock picking, and asset allocation in today's market.
Source: SeekingAlpha
Why I Sold Pfizer To Buy Novo Nordisk
9/14/2025
While Pfizer's market cap and dividends are at risk, Novo has a strong competitive position in GLP-1 TAM. Read why I prefer NVO stock over PFE stock.
Source: SeekingAlpha
The GLP-1 Oral Frontier: Novo Nordisk And Eli Lilly's 100-Year Duel Enters Its Next Chapter
9/13/2025
Nordisk and Eli Lilly are set to reshape the oral GLP-1 market as patient demand grows and new therapies emerge. Learn more on LLY and NVO stocks here.
Source: SeekingAlpha
BDC Weekly Review: BDCs Busy Bringing Bonds To Market
9/13/2025
BDCs dipped slightly as bond issuance rises and leverage builds to support income amid rate shifts. Read why these trends matter for the sector outlook.
Source: SeekingAlpha
Novo Nordisk: GLP-1's Concerns Are Overblown
9/13/2025
Novo Nordisk leads globally in GLP-1s despite U.S. pressure, with a strong pipeline, cost cuts, and attractive valuation. Find out why NVO stock is a buy.
Source: SeekingAlpha